At Merck, Business Development As Usual?
Merck's newly appointed SVP for world-wide licensing, C. David Nicholson, outlines the Big Pharma's dealmaking priorities at Elsevier Business Intelligence's February BIO-Windhover Pharmaceutical Strategic Outlook meeting.
You may also be interested in...
Merck contributes to Flagship’s latest fund, both sides promise to share ideas and expertise, but Merck gets no special rights to companies or products in Flagship’s portfolio.
Merck’s new head of worldwide licensing and knowledge management Roger Pomerantz, MD, talks with IN VIVO about Merck’s business development strategy, whether biotech passion can exist on a Big Pharma scale, and the art of the deal.
Competition for biotech’s most eligible assets has never been stronger. As such, some pharmas are trying harder than ever to get in on the ground floor.